Delcath Systems Inc (DCTH) Stock Price

DCTHStock
$16.92+50.63%52W
Market Cap$587.10M
P/E220.21x
PEG Ratio1.60
Div yield
Beta0.59

DCTH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)65.44%
Price vs S&P 500 (4W)41.97%
PEG Ratio1.60
VGM Score54.96
P/E Ratio (Annual)220.21x

DCTH Earnings Surprise History

Q2 250.07est. 0.03
Q3 250.02est. -0.09
Q4 25-0.05est. -0.03
Q1 26-0.03est. -0.09
Q2 260.07est. -0.09

DCTH Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.23
4.23
4.17
4.17

Industry Peers — Surgical & Medical Instruments(140)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
DCTHDelcath Systems Inc
DBA$16.92
SYKStryker CorporationCBC$330.59
MMM3M CompanyCDB$179.37
BSXBoston Scientific Corp.CBD$49.86
BDXBecton, Dickinson and Co.BDB$189.78
MDLNMedline Inc. Class A common stockCDC$35.64
RMDResMed Inc.CBC$236.59
DXCMDexCom, Inc.DBB$89.16
WSTWest Pharmaceutical Services, Inc.DCB$348.48
SOLVSolventum CorporationCCB$91.61
BAXBaxter International Inc.BDB$26.29

About Delcath Systems Inc

Delcath Systems develops a drug-device combination for treating primary and metastatic liver cancers. Its proprietary Melphalan Hepatic Delivery System administers high-dose chemotherapy directly to the liver while minimizing systemic exposure and associated side effects. The company manufactures and distributes its products across the United States and Europe.